News

Cytokinetics has agreed with GlaxoSmithKline (GSK) to terminate their collaboration and license agreement, effective February 28, 2010. As a result, all rights for GSK-923295, an inhibitor of centromere-associated

Findings from a newly released study by KMR Group found that the time it takes to get a site contract approved is five to six weeks on average.

Dishman Pharmaceuticals and Chemicals has entered into a joint venture with three pharmaceutical companies in Saudi Arabia. The new venture will manufacture active pharmaceutical ingredients (API), reported Business

Lotus Pharmaceuticals (Lotus) has reported that Liang Fang, a controlled operating entity of Lotus has appointed Jinzhong Han as a general manager of the company’s over-the-counter drug division

Critical Outcome Technologies (COTI) has announced positive results from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the

Access has provided an update on the European commercial launch of its MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and

Sanofi-aventis and Alopexx Pharmaceuticals have entered into a collaboration agreement and option for a license on a first-in-class human monoclonal antibody for the prevention and treatment of S

Biomoda has reported that the Helen F. Graham Cancer Center associated with Christiana Care Health System, will recruit a cohort of patients diagnosed with lung cancer to participate

Bayer Schering Pharma’s first Phase II trial with oral agent Riociguat (BAY 63-2521) in pulmonary hypertension, owing to interstitial lung disease (PH-ILD), has successfully been completed. The primary